Morgan Stanley Comments on Pfizer Meeting

In a research report published earlier today, Morgan Stanley commented on the recent Pfizer PFE Emerging Markets & Established Products meeting. According to Morgan Stanley, “On Friday March 30th, we met with David Simmons, President of Emerging Markets (EM) and Established Products (EP), and Susan Silverman, Head of LatAm. We found both to be quite impressive and direct. EM and EP are each approximately $10 billion operations (each 15% of total Pfizer revenue). Four takeaways were: 1) we expect Pfizer to retain EP, 2) generics M&A likely to be niche, 3) U.S. Lipitor strategy is working, and 4) EM should accelerate.” Morgan Stanley maintains its Overweight rating on Pfizer, which closed Friday at $22.66.